Kalaris Therapeutics Q1 EPS $(2.52) Misses $(1.17) Estimate

Kalaris Therapeutics (NASDAQ: KLRS) reported quarterly losses of $(2.52) per share which missed the analyst consensus estimate of $(1.17) by 115.38 percent. This is a 3.08 percent increase over losses of $(2.60) per share from the same period last year.